PHARMA - Mobio Interactive

Pharma
 
Digitally-enabled pharmacotherapy, theragnostics, and mental health endpoints. 
The greatest challenges facing the pharmaceutical industry today include changing patient expectations, increased self-medication, difficulties in identifying novel medicines for incurable diseases, high payer scrutiny of pharma-economic performance, the trend for governments to favour prevention over treatment, and access to emerging markets. Partnering with MI helps turn these challenges into opportunities.
 
Patient Testimonials

 
"…it was helping me get through my post cancer treatments and my cancer that has been a very very rough journey."

Breast cancer survivor (double mastectomy)
 

 
"... this [digital therapeutic] forced me to block out the world and say okay, this moment is mine right now, and I'm going to enjoy this moment for myself."

Testicular cancer survivor (chemotherapy)

 
"…I felt like it was an actual meditation – like they were actually there with me."

Kidney cancer survivor (immunotherapy)
 
 

What we offer✓ Delivery of clinical resilience training at scale
✓ Objective data insights and resilience content preferences
✓ Full backend integration for policyholder verification
✓ A digital biomarker SDK and psychotherapy library API that plugs into existing systems

Rx + DTx Pairing

Improve efficacy & patient experience
 
Accelerate market access & reimbursement

Standalone DTx

Generate compound-agnostic revenue
 
Access actionable patient data

Clinical Endpoints

Capture objective biometrics remotely
 
Augment mental wellbeing assessment

Certifications

Mobio Interactive’s digital therapeutic platform “AmDTx” is CE MDD Class I and DCB0129 certified; GDPR-, HIPAA- and PHIPA-compliant; and undergoing certification for CE MDR Class IIa, ISO 13485, ISO 9000 and ISO 27001.

Clinical Trials

Validating the accuracy of our digital biomarkers and the efficacy of our digital theragnostic platform, AmDTx.